Hervé Wallerand

FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.

Ashraf Bakkar, Hervé Wallerand, François Radvanyi et al. · PubMed · 2003 · 272 citations

Medicine, Genetics, Oncology +15

N-Cadherin as a Novel Prognostic Marker of Progression in Superficial Urothelial Tumors

Isabelle Lascombe, Anne Clairotte, Sylvie Fauconnet et al. · Clinical Cancer Research · 2006 · 104 citations · Full text

Medicine, Oncology, Pathology +16

Renal Cell Carcinoma (RCC) in Patients With End-Stage Renal Disease Exhibits Many Favourable Clinical, Pathologic, and Outcome Features Compared With RCC in the General Population

Y. Neuzillet, X. Tillou, Romain Mathiéu et al. · European Urology · 2011 · 99 citations

Medicine, Oncology, Pathology +11

Interpretation of Positive Flow Cytometric Crossmatch in the Era of the Single-Antigen Bead Assay

Lionel Couzi, Caroline Pacheco Araújo, Gwendaline Guidicelli et al. · Transplantation · 2010 · 92 citations

Life Sciences, Immunology, Nephrology +17

Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens

Hervé Wallerand · Carcinogenesis · 2004 · 87 citations · Full text

Medicine, Oncology, Urology +17